This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
5 High-Flying Corporate Giants Set to Beat on Q3 Earnings
by Nalak Das
Despite almost day-to-day market fluctuations, a few corporate behemoths surged in Wall Street. Some of these are set to beat earnings estimate in the ongoing reporting cycle.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $202.93, moving +0.1% from the previous trading session.
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Alexion Gets FDA Approval for Label Expansion of Ultomiris
by Zacks Equity Research
Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.
Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?
by Zacks Equity Research
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Alexion to Buy Achillion for $930M, Strengthen PNH Franchise
by Zacks Equity Research
Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.
Roche Posts Solid Sales for First 9 Months of '19, Ups View
by Zacks Equity Research
Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $204.66, marking a +0.87% move from the previous day.
Lilly Gets FDA Approval for New Oral Tablets for Migraine
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Roche Announces Positive Late-Stage Data on Rituxan in PV
by Zacks Equity Research
Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Alexion (ALXN) Collaborates With Stealth BioTherapeutics
by Zacks Equity Research
Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.
Top Research Reports for Toyota, Amgen & TJX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), Amgen (AMGN) and The TJX Companies (TJX).
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $196.69, moving +0.31% from the previous trading session.
Why Alexion is a Hot Takeover Target in the Biotech Sector
by Zacks Equity Research
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.
Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMGN) Outperforming Other Medical Stocks This Year?
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $192.62, marking a +1.8% move from the previous day.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Ranked Income Stocks to Buy for October 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.